Barclays raised the firm’s price target on MacroGenics to $23 from $12 and keeps an Overweight rating on the shares. The analyst previeed the initial Phase 2 data in prostate cancer in the first half of 2024, saying positive would be to show signs of improved safety and PSA50 in line with prior data. The firm sees a high probability of positive data.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MGNX:
- MacroGenics Announces Date of Fourth Quarter 2023 Financial Results Conference Call
- MGNX Upcoming Earnings Report: What to Expect?
- MacroGenics downgraded to Neutral from Buy at H.C. Wainwright
- MacroGenics to Participate in Upcoming Investor Conference
- Cantor Fitzgerald biotech analysts hold an analyst/industry conference call
